Skip to main content
Triangle logo TriangleGet started

CYT107 (NCT07308886)

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV): a one-minute explainerNCT073088861 min

CYT107 trial for Kaposi Sarcoma (NCT07308886). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with HIV-associated Kaposi sarcoma despite suppressive antiretroviral treatment, CD4 counts of 350 or less, and at least five measurable skin lesions.

The idea: CYT107 is interleukin-7, which supports T-cell growth. Patients receive weekly muscle injections for up to four doses. A second course depends on immune-cell changes and cancer response. Researchers measure lesions and blood counts; skin biopsies may be taken. Antiretroviral therapy must continue.

This phase 2 study plans 55 patients. Ramya Ramaswami leads at the NIH Clinical Center in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.